TY - JOUR
T1 - Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography
T2 - A randomised controlled trial
AU - the Scottish COmputed Tomography of the HEART (SCOT-HEART) Trial Investigators
AU - Williams, Michelle C.
AU - Hunter, Amanda
AU - Shah, Anoop
AU - Assi, Valentina
AU - Lewis, Stephanie
AU - Mangion, Kenneth
AU - Berry, Colin
AU - Boon, Nicholas A.
AU - Clark, Elizabeth
AU - Flather, Marcus
AU - Forbes, John
AU - McLean, Scott
AU - Roditi, Giles
AU - Van Beek, Edwin J.R.
AU - Timmis, Adam D.
AU - Newby, David E.
AU - Pawade, Tania
AU - Flapan, Andrew
AU - Hargreaves, Allister
AU - Leslie, Stephen
AU - Lewis, Steff
AU - McKillop, Graham
AU - Reid, John
AU - Spratt, James
AU - Uren, Neal
AU - Clark, Liz
AU - Craig, Peter
AU - Barlow, Tom
AU - McCormack, Chiara
AU - Shepherd, Susan
AU - Bucukoglu, Marise
AU - Parker, Richard
AU - Krishan, Ashma
AU - Wee, Fiona
AU - Wackett, Anthony
AU - Walker, Allan
AU - Milne, Lynsey
AU - Oatey, Kat
N1 - Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events. The effect on patient symptoms is currently unknown. Methods In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA. Symptoms and quality of life were assessed over 6 months using the Seattle Angina Questionnaire and Short Form 12. Results Baseline scores indicated mild physical limitation (74±0.4), moderate angina stability (44±0.4), modest angina frequency (68±0.4), excellent treatment satisfaction (92±0.2) and moderate impairment of quality of life (55±0.3). Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference -1.74 (95% CIs, -3.34 to -0.14), p=0.0329), angina frequency (difference -1.55 (-2.85 to -0.25), p=0.0198) and quality of life (difference -3.48 (-4.95 to -2.01), p<0.0001) at 6 months. For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all). Conclusions While improving diagnosis, treatment and outcome, CTCA is associated with a small attenuation of the improvements in symptoms and quality of life due to the detection of moderate non-obstructive coronary artery disease.
AB - Background In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events. The effect on patient symptoms is currently unknown. Methods In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA. Symptoms and quality of life were assessed over 6 months using the Seattle Angina Questionnaire and Short Form 12. Results Baseline scores indicated mild physical limitation (74±0.4), moderate angina stability (44±0.4), modest angina frequency (68±0.4), excellent treatment satisfaction (92±0.2) and moderate impairment of quality of life (55±0.3). Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference -1.74 (95% CIs, -3.34 to -0.14), p=0.0329), angina frequency (difference -1.55 (-2.85 to -0.25), p=0.0198) and quality of life (difference -3.48 (-4.95 to -2.01), p<0.0001) at 6 months. For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all). Conclusions While improving diagnosis, treatment and outcome, CTCA is associated with a small attenuation of the improvements in symptoms and quality of life due to the detection of moderate non-obstructive coronary artery disease.
UR - http://www.scopus.com/inward/record.url?scp=85020520852&partnerID=8YFLogxK
U2 - 10.1136/heartjnl-2016-310129
DO - 10.1136/heartjnl-2016-310129
M3 - Article
C2 - 28246175
AN - SCOPUS:85020520852
SN - 1355-6037
VL - 103
SP - 995
EP - 1001
JO - Heart
JF - Heart
IS - 13
ER -